HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

SHC

Sotera Health Company (NASDAQ)

Healthcare — Diagnostics & Research

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Buy 1.7 / 5 9 analysts
$17.87
+$0.12 (+0.68%)
Target: $20.22 (13.2%)
Sign in to add SHC to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$5.10B
P/E Ratio (TTM)43.61
Forward P/E16.82
EPS (TTM)$0.41
Dividend Yield-
Profit Margin9.91%
Revenue Growth10.00%
ROE22.73%
Debt/Equity364.72
Recommendation Buy 1.7
Analyst Target$20.22
Analysts9
Indexes NASDAQ

Technical Indicators

RSI (14)70.7
Beta1.80
SMA 20-
SMA 40-
52-Week High$19.85
52-Week Low$10.94
50-Day Avg$15.87
200-Day Avg$16.29
Avg Volume$3.22M
Volume15.9K

Performance Analysis

BULLISH

SHC shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 78% of its 52-week range.
- RSI at 70.7 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 43.6 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 10.0% year-over-year.
+ Wall Street consensus is "Buy" from 9 analysts.
+ Average analyst target of $20.22 implies 13.2% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:31 UTC

Back to Screener Export Report